Malignant Melanoma
暂无分享,去创建一个
Eshini Perera | Neiraja Gnaneswaran | Ross Jennens | Rodney Sinclair | Eshini Perera | Neiraja Gnaneswaran | Ross Jennens | Rodney Sinclair
[1] C. Longo,et al. De novo melanoma and melanoma arising from pre-existing nevus: in vivo morphologic differences as evaluated by confocal microscopy. , 2011, Journal of the American Academy of Dermatology.
[2] J. Larkin,et al. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm , 2013, Therapeutic advances in medical oncology.
[3] Gerard J Fitzsimmons,et al. From the Australian Institute of Health and Welfare , 2014, Communicable diseases intelligence quarterly report.
[4] M. Tucker,et al. Increased risk of second primary cancers after a diagnosis of melanoma. , 2010, Archives of dermatology.
[5] E. Pauwels,et al. Ocular melanoma. , 1990, The British journal of ophthalmology.
[6] J. Kirkwood,et al. IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.
[7] J. Wilmott,et al. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.
[8] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[9] David C. Smith,et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[11] P. Boyle,et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. , 2005, European journal of cancer.
[12] F. Kelleher,et al. Targeting NRAS in Melanoma , 2012, Cancer journal.
[13] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[14] K. Flaherty,et al. From genes to drugs: targeted strategies for melanoma , 2012, Nature Reviews Cancer.
[15] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[17] R. Elashoff,et al. Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.
[18] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Christopher J. Miller,et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. , 2012, Journal of the American Academy of Dermatology.
[20] Ana Alekseenko,et al. Dermoscopy - the essentials. , 2009 .
[21] R. Gutzmer,et al. Prognostic Significance of Isolated HMB45 or Melan A Positive Cells in Melanoma Sentinel Lymph Nodes , 2007, The American journal of surgical pathology.
[22] J. Manola,et al. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.
[23] T. Fitzpatrick,et al. Adjuvant therapy for melanoma. , 1983, Surgery.
[24] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Lens,et al. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. , 2003, The Lancet. Oncology.
[26] R. Fisher,et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. , 2012, The Lancet. Oncology.
[27] P. Ascierto,et al. Update on PEG-interferon α-2b as adjuvant therapy in melanoma. , 2012, Anticancer research.
[28] J. Wolchok,et al. Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses? , 2012, American journal of clinical oncology.
[29] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Sosman,et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. , 2002, Cancer.
[31] T. Fitzpatrick,et al. Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma. Report of two cases. , 1983, Archives of dermatology.
[32] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[33] G. Barsh,et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .
[34] I. Puzanov,et al. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. , 2012, Future oncology.
[35] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[36] J. O'Brien,et al. Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.
[38] P. Boyle,et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. , 2005, European journal of cancer.
[39] P. Boyle,et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. , 2005, European journal of cancer.
[40] G. Gibney,et al. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies , 2013, Expert opinion on drug metabolism & toxicology.
[41] M. Gore,et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.
[42] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[43] V. Bataille. Early detection of melanoma improves survival. , 2009, Practitioner.
[44] J. J. Coleman,et al. Patterns of Initial Recurrence and Prognosis after Sentinel Lymph Node Biopsy and Selective Lymphadenectomy for Melanoma , 2003, Plastic and reconstructive surgery.
[45] D. Tyler,et al. Long-Term Survival in 2,505 Patients With Melanoma With Regional Lymph Node Metastasis , 2002, Annals of surgery.
[46] K. Flaherty,et al. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). , 2013 .
[47] S. Mocellin,et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. , 2013, The Cochrane database of systematic reviews.
[48] R. Dummer,et al. Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.
[49] Y. Samuels,et al. Analysis of the genome to personalize therapy for melanoma , 2010, Oncogene.
[50] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Kugler,et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J. Wolchok,et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[55] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.
[56] F. Tas. Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors , 2012, Journal of oncology.
[57] V. Huang,et al. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. , 2012, Archives of dermatology.
[58] R. Kurzrock,et al. BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance , 2013, Oncotarget.